Table 3.
Inhibitor (conc.) |
SER |
RER |
||||
---|---|---|---|---|---|---|
Control |
+ Inhibitor |
Control |
+ Inhibitor |
|||
pmol/mg protein | pmol/mg protein | % of control | pmol/mg protein | pmol/mg protein | % of control | |
E17βG (100 μM) | 37 ± 2 | 20 ± 1*** | 53 ± 3 | 18 ± 3 | 13 ± 2* | 71 ± 3 |
E3S (100 μM) | 33 ± 5 | 20 ± 4* | 60 ± 5 | 17 ± 4 | 12 ± 3 | 71 ± 5 |
UDPGA (4 mM) | 38 ± 2 | 36 ± 5 | 94 ± 8 | 17 ± 3 | 15 ± 3 | 88 ± 3 |
Stx64 (1 μM) | 38 ± 3 | 34 ± 5 | 90 ± 7 | 18 ± 2 | 17 ± 4 | 94 ± 12 |
G6P (1 mM) | 36 ± 3 | 32 ± 1 | 90 ± 5 | 23 ± 5 | 21 ± 5 | 88 ± 7 |
Vanadate (1 mM) | 36 ± 3 | 33 ± 1 | 93 ± 5 | 23 ± 5 | 21 ± 4 | 92 ± 5 |
Vanadate (1 mM) G6P (1 mM) | 36 ± 3 | 32 ± 2 | 90 ± 5 | 23 ± 5 | 20 ± 4 | 87 ± 9 |
Data of TC uptake in absence (Control) and presence (+ Inhibitors) of the given inhibitors are given as mean pmol/mg protein ± SD of at least 3 independent experiments using vesicles from different vesicle preparations. Statistically significant difference in uptake rates compared to the control is given in bold. P-values are indicated by asterisks as followed: * for p < 0.05 and *** for p < 0.001.